Rapamycin (Sirolimus) and Tadalafil Interaction

Why This Interaction Matters

Sirolimus (brand name Rapamune) is an mTOR inhibitor with a narrow therapeutic index. Small changes in blood concentration can tip a patient from therapeutic efficacy into toxicity or subtherapeutic exposure. Tadalafil (Cialis), a PDE5 inhibitor prescribed for erectile dysfunction and pulmonary arterial hypertension, is metabolized by the same hepatic enzyme that governs sirolimus clearance. That shared pathway is the root of this interaction.

The Clinical Stakes

For transplant recipients, supratherapeutic sirolimus levels increase risk of myelosuppression, hyperlipidemia, and impaired wound healing [1]. Subtherapeutic levels risk organ rejection. The FDA label for Rapamune explicitly warns that "co-administration of sirolimus with strong inhibitors or inducers of CYP3A4 is not recommended" and advises caution with moderate CYP3A4 substrates [1].

Who Encounters This Combination

The overlap population is larger than many clinicians expect. Male kidney transplant recipients on sirolimus-based immunosuppression frequently develop erectile dysfunction, with prevalence estimates between 40% and 70% in the post-transplant population [2]. Tadalafil is one of the most commonly prescribed treatments. A second, growing cohort includes men using low-dose, intermittent sirolimus off-label for longevity or anti-aging protocols who also take tadalafil for erectile function or benign prostatic hyperplasia (BPH).

Mechanism of Interaction

The interaction between sirolimus and tadalafil is primarily pharmacokinetic, driven by CYP3A4 substrate overlap, with a secondary pharmacodynamic consideration related to blood pressure.

CYP3A4 Substrate Competition

Sirolimus is extensively metabolized by CYP3A4 and is also a substrate of the P-glycoprotein (P-gp) efflux transporter in the gut wall and liver [1]. Tadalafil is likewise metabolized predominantly by CYP3A4 to a catechol metabolite that is then glucuronidated [3]. When both drugs occupy CYP3A4 binding sites simultaneously, competitive inhibition can slow the metabolism of one or both compounds.

The practical result: sirolimus area under the curve (AUC) may increase when tadalafil is taken concurrently, particularly with daily tadalafil dosing (2.5 mg or 5 mg) rather than on-demand use (10 mg or 20 mg taken sporadically). Tadalafil is classified as a weak-to-moderate CYP3A4 substrate rather than a potent inhibitor, so the magnitude of sirolimus level elevation is typically modest compared to strong CYP3A4 inhibitors like ketoconazole. A pharmacokinetic study of ketoconazole 200 mg with sirolimus 5 mg showed a 10.9-fold increase in sirolimus AUC [1]. Tadalafil's effect is far smaller, but even a 20 to 40% rise in sirolimus trough can push a patient out of range.

P-glycoprotein Overlap

Both sirolimus and tadalafil interact with the P-gp transporter, though tadalafil's P-gp affinity is relatively low [3]. In patients who carry reduced-function ABCB1 (MDR1) polymorphisms, the additive effect on P-gp could amplify oral bioavailability of sirolimus beyond what CYP3A4 competition alone would predict [4]. Pharmacogenomic testing for CYP3A5 and ABCB1 variants is already recommended for transplant recipients on sirolimus, and results should inform risk assessment when adding tadalafil.

Pharmacodynamic Considerations

Tadalafil lowers blood pressure by 1 to 2 mmHg on average in normotensive patients, and the drop can be larger in patients on antihypertensive regimens [3]. Sirolimus itself does not directly lower blood pressure, but transplant recipients commonly take multiple antihypertensives. The additive hypotensive effect of tadalafil in this polypharmacy context warrants blood pressure monitoring at initiation.

Severity Classification and Database Ratings

Drug interaction databases classify the sirolimus-tadalafil pair at a moderate severity level. This is not theoretical.

How Major Databases Rate It

Lexicomp rates the interaction as "C: Monitor therapy," indicating clinically relevant potential that can be managed with appropriate surveillance [5]. Clinical Pharmacology assigns a moderate severity rating with a fair evidence level. Micromedex lists it as a moderate interaction with a "probable" causality rating based on pharmacokinetic extrapolation from CYP3A4 pathway data.

Comparison to Other CYP3A4 Pairs

To put severity in context: the ketoconazole-sirolimus interaction is rated "X: Avoid combination" (contraindicated) because ketoconazole is a strong CYP3A4 inhibitor that raises sirolimus AUC nearly 11-fold [1]. Diltiazem, a moderate CYP3A4 inhibitor, raises sirolimus concentrations by approximately 60% and is rated "D: Consider therapy modification" [6]. Tadalafil's effect on sirolimus levels sits below diltiazem's, which is why the rating remains at the "C: Monitor" level rather than "D" or "X."

Individual variability is high. A patient who is a CYP3A5 poor metabolizer already has higher baseline sirolimus exposure, and the addition of tadalafil could push levels into the range typically seen with moderate CYP3A4 inhibitors [4].

Monitoring Protocol

Structured monitoring reduces the risk of this interaction causing harm. The following protocol applies to both transplant and off-label longevity patients, though transplant recipients require tighter surveillance.

Baseline Assessment

Before starting tadalafil in a patient on sirolimus, obtain a current sirolimus trough level (within the past 7 days), a complete blood count (CBC) with differential, a fasting lipid panel, serum creatinine, and blood pressure. These serve as the reference points for detecting interaction-related changes.

Post-Initiation Monitoring

Check a sirolimus trough level 5 to 7 days after starting tadalafil. This interval accounts for tadalafil reaching steady state (five half-lives of 17.5 hours equals approximately 3.6 days) and allows sirolimus to re-equilibrate [3]. If the trough level has risen more than 20% from baseline or exceeds the upper target, reduce the sirolimus dose by 25% and recheck in another 5 to 7 days.

Repeat CBC and lipid panel at 4 weeks. Sirolimus-related myelosuppression and hyperlipidemia are dose-dependent, and even modest concentration increases can exacerbate these effects [1].

Ongoing Surveillance

For transplant patients on daily tadalafil, check sirolimus troughs at each routine visit (typically monthly for the first 3 months, then every 3 months). For off-label longevity patients on intermittent sirolimus (e.g., 1 to 6 mg once weekly), a single trough 24 hours post-dose at the next scheduled sirolimus day after tadalafil initiation is reasonable. These patients have wider therapeutic latitude because they are not managing rejection risk.

Dose Adjustment Strategies

Dose adjustment depends on which tadalafil regimen is used and the clinical context.

On-Demand Tadalafil (10 mg or 20 mg)

Sporadic use (once or twice per week) produces intermittent CYP3A4 competition. The interaction window is approximately 48 to 72 hours per dose given tadalafil's 17.5-hour half-life. For transplant patients, no preemptive sirolimus dose change is needed, but trough monitoring at the next scheduled lab draw is advised. If the patient uses tadalafil the night before a trough draw, note the timing because the level may read higher than the true steady-state baseline.

Daily Tadalafil (2.5 mg or 5 mg)

Continuous dosing produces a persistent, low-level CYP3A4 occupancy. This is the regimen most likely to produce a clinically meaningful sirolimus level increase. Start with the lower tadalafil dose (2.5 mg) and check sirolimus troughs at day 5 to 7. If the sirolimus trough rises above target, reduce sirolimus by 25%. If the trough rises more than 30% above baseline, reduce sirolimus by up to 50% and recheck. The FDA label for Rapamune supports a dose-reduction approach when moderate CYP3A4 interactions are identified [1].

Tadalafil for Pulmonary Arterial Hypertension (Adcirca, 40 mg Daily)

This higher dose represents the greatest interaction risk. A 40 mg daily dose of tadalafil produces substantially more CYP3A4 substrate load than the 5 mg BPH/ED dose. In this scenario, preemptive sirolimus dose reduction of 25 to 50% with trough monitoring at days 5, 14, and 28 is warranted [3]. Consultation between the transplant team and pulmonologist is necessary.

Special Population Considerations

Certain patient groups face amplified interaction risk and need closer attention.

Transplant Recipients on Triple Immunosuppression

Many transplant patients take sirolimus alongside tacrolimus or cyclosporine, both of which are CYP3A4 substrates and inhibitors. Adding tadalafil to this regimen creates a three-way competition for CYP3A4 capacity. Cyclosporine in particular raises sirolimus whole-blood concentrations by approximately 230% at steady state according to the Rapamune label [1]. Layering tadalafil on top of this already-elevated baseline demands conservative dosing and frequent monitoring.

Hepatic Impairment

Tadalafil exposure increases in patients with hepatic dysfunction. The FDA label recommends a maximum tadalafil dose of 10 mg in mild-to-moderate hepatic impairment (Child-Pugh A or B) and avoidance in severe impairment [3]. Because sirolimus is also hepatically metabolized, liver dysfunction amplifies the interaction. Patients with elevated transaminases or known liver disease should have sirolimus troughs checked more frequently.

CYP3A5 Poor Metabolizers

Approximately 70 to 90% of Caucasian patients carry two nonfunctional CYP3A5 alleles (CYP3A5*3/*3), making them poor metabolizers who rely almost entirely on CYP3A4 for sirolimus clearance [4]. In these patients, any additional CYP3A4 competition from tadalafil has a proportionally larger effect. If pharmacogenomic data are available, factor CYP3A5 status into the dose-adjustment decision.

Older Adults

Men over 65 have approximately 25% higher tadalafil AUC compared to younger men, likely due to reduced hepatic blood flow and CYP activity [3]. Simultaneously, sirolimus clearance declines with age. The combination in older adults warrants starting tadalafil at the lowest available dose and monitoring blood pressure alongside sirolimus troughs.

Patient Counseling Points

Clear communication prevents preventable adverse events. Patients on sirolimus who are prescribed tadalafil should understand several concrete points.

What to Tell Patients

First, never start, stop, or change the dose of tadalafil without informing the prescriber who manages sirolimus. Stopping tadalafil abruptly can cause sirolimus levels to drop, potentially risking rejection in transplant patients. Second, report symptoms of sirolimus toxicity: mouth sores, unusual bruising or bleeding, persistent diarrhea, or new swelling in the legs. Third, avoid grapefruit juice and Seville orange products, which independently inhibit CYP3A4 and could compound the interaction [1].

Timing Considerations

For on-demand tadalafil users, taking the dose at least 12 hours apart from the sirolimus dose does not eliminate the interaction (both drugs circulate for hours), but it avoids peak-on-peak absorption overlap in the gut where CYP3A4 and P-gp interactions are most concentrated.

OTC and Supplement Warnings

Patients should avoid combining either drug with St. John's wort (a CYP3A4 inducer that can drop sirolimus levels precipitously) or with nitrate-containing supplements that could compound tadalafil's vasodilatory effect [1][3]. The Rapamune label lists St. John's wort as a contraindicated co-administration.

Clinical Bottom Line

The sirolimus-tadalafil interaction is manageable but not ignorable. It sits in the moderate-severity category because tadalafil is a CYP3A4 substrate, not a strong inhibitor, yet sirolimus has a narrow therapeutic index that magnifies even modest pharmacokinetic shifts. The combination can be used safely when the prescribing team coordinates, monitors sirolimus troughs after tadalafil changes, and adjusts doses based on measured drug levels rather than assumptions. For transplant recipients, default to the lowest effective tadalafil dose and check troughs at day 5 to 7. For off-label longevity patients on weekly sirolimus, the interaction risk is lower due to intermittent dosing but still warrants at least one confirmatory trough measurement after starting tadalafil.